IBRX - ImmunityBio, Inc.
ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer and Check
Did you buy CAPR securities between December 17, 2025 and July 26, 2026? Affected CAPR Investor Summary Who: Capricor Therapeutics, Inc. (NASDAQ: CAPR) What: Securities fraud class action lawsuit filed Class Period: December 17, 2025 through July 26, 2026 Deadline to Seek Lead Plaintiff Status: September 28, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's lead product candidates statistical analysis plan and FDA compliance Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options RADNOR, Pa.
Bell and Brown Wealth Advisors LLC purchased a new stake in ImmunityBio, Inc. (NASDAQ: IBRX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 75,050 shares of the company's stock, valued at approximately $657,000. A number of other large investors have also
Bank of America Corp DE grew its stake in shares of ImmunityBio, Inc. (NASDAQ: IBRX) by 2.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,447,843 shares of the company's stock after purchasing an additional 65,340 shares during the quarter. Bank of
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Jim Yong Kim has joined the company as Vice Chairman. Dr. Kim will serve in a newly created Office of the Executive Chairman, where he will focus on strengthening the company's international and global relationships. He will report to Executive Chairman and Founder Dr. Patrick Soon-Shiong. The Office of the Executive Chairman will bring together senior leade.
ImmunityBio beat Q2 earnings and revenue estimates as record Anktiva sales and continued adoption fuel growth, with more regulatory milestones ahead.
ImmunityBio (IBRX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.1 per share a year ago.
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage biotechnology company, today announced financial and operational results for the second quarte
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, today announced financial and operational results for the second quarter ended June 30, 2026. Net product revenue reached $50.7 million, representing 92% year-over-year growth and 15% sequential growth from the first quarter of 2026. The Company also advanced multiple regulatory and clinical programs across its immunotherapy pipeline while achieving its eighth consecutive quarter of.
The Emirates Drug Establishment (EDE) in the United Arab Emirates on Thursday approved ImmunityBio Inc.'s (NASDAQ:IBRX) immunotherapy drug, ANKTIVA.
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage biotechnology company, today announced that the Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) has granted Marketing Authorization for ANKTIVA® (nogapendekin alfa inbakicept) across two indications. The authorization covers ANKTIVA 0.4 mg in combination with BCG for the treatment of adult patients with BCG-unresponsive NMIBC, and ANKTIVA 1.2 mg in combination wit.
ImmunityBio earns a cautious buy rating as Anktiva demonstrates strong efficacy and safety in NMIBC and shows promise across broader oncology indications. IBRX's valuation now reflects significant future revenue; rapid share appreciation and anticipated dilution temper near-term upside despite robust revenue ramp and pipeline catalysts. Anktiva's combination with BCG outperforms competitors, with 84% CR in BCG-naïve NMIBC and potential label expansion pending FDA decision in early 2027.
ImmunityBio offers a best-in-class, approved immunotherapy, ANKTIVA, driving rapid revenue growth and significant market share in NMIBC. IBRX's pipeline is robust, with multiple Phase 1-3 trials targeting NSCLC, glioblastoma, HIV, and other high-value indications, supporting long-term upside. The recent 40% pullback from 52-week highs creates an attractive entry point, with strong balance sheet support and no immediate financial risks.
Short‑interest screens are lighting up with a tight cluster of mid‑ and large‑cap names where bearish bets have gone all‑in, turning these stocks into live‑wire squeeze candidates rather than sleepy laggards.
Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.
ImmunityBio is pivoting from a single-product Anktiva focus to a broad immunotherapy platform, emphasizing memory-like cytokine-enriched NK cells (M-ceNK). Key near-term catalysts include the pivotal QUILT-2.005 bladder cancer trial, lymphopenia indication expansion, and the glioblastoma (GBM) program, each validating the immune-restoration thesis. IBRX trades at a significant premium (65x trailing sales, 44x forward sales), reflecting high expectations for Anktiva's transition to first-line therapies and broader platform validation.
ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2, 2026, in Chicago. The presentations span two randomized Phase 3 trials in advanced NSCLC and a matched adjusted indirect comparison (MAIC) in BCG unresponsive non-muscle invasive bladder cancer (NMIBC), and collectively e.
ImmunityBio targets the BCG shortage with new supply deals and label expansion efforts that could strengthen Anktiva demand in bladder cancer.